Dormoi J et al., 2013-04-22: Mouse study of Proveblue (pharmaceutical-grade methylene blue) in experimental cerebral malaria: 10 mg/kg rescued 78% of infected mice, the same as the dihydroartemisinin combination, while all untreated and all dihydroartemisinin-only mice died.
78% of mice treated with 10 mg/kg Proveblue (methylene blue) and 78% of mice treated with a combination of 3 mg dihydroartemisinin and 10 mg/kg Proveblue survived and showed no specific signs of cerebral malaria or detectable parasites.
Abstract
Dormoi J et al., 2013-04-22: Mouse study of Proveblue (pharmaceutical-grade methylene blue) in experimental cerebral malaria: 10 mg/kg rescued 78% of infected mice, the same as the dihydroartemisinin combination, while all untreated and all dihydroartemisinin-only mice died. Study type: animal (murine experimental cerebral malaria, Plasmodium berghei ANKA). Product tested: Proveblue (methylene blue, Provepharm, France) , the only item in this claim naming a commercial maker. Dose 10 mg/kg (route not in abstract; intraperitoneal in the full text). Comparator: untreated mice, dihydroartemisinin 3 mg/kg, and the combination. Funder/COI not stated in retrieved abstract record; French military (IMTSSA/URMITE) group. Animal data only , must not be read as human efficacy. Study type: animal.
